Arcus biosciences announces new employment inducement grants

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the compensation committee of the company's board of directors granted three new employees options to purchase a total of 10,000 shares of the company's common stock at an exercise price per share of $14.56, which was the closing price on november 25, 2024,.
RCUS Ratings Summary
RCUS Quant Ranking